Affiliation:
1. Department of Internal Medicine 1, Faculty of Medicine Shimane University Izumo Japan
2. The Center for Integrated Kidney Research and Advance, Faculty of Medicine Shimane University Izumo Japan
Abstract
AbstractThe association of type 2 diabetes with certain cancer risk has been of great interest for years. However, the effect of diabetic medications on cancer development is not fully understood. Prospective clinical trials have not elucidated the long‐term influence of hypoglycemic drugs on cancer incidence and the safety for cancer‐bearing patients with diabetes, whereas numerous preclinical studies have shown that antidiabetic drugs could have an impact on carcinogenesis processes beyond the glycemic control effect. Because there is no evidence of the safety profile of antidiabetic agents on cancer biology, careful consideration would be required when prescribing any medicines to patients with diabetes and existing tumor. In this review, we discuss the potential influence of each diabetes therapy in cancer ‘initiation’, ‘promotion’ and ‘progression’.
Funder
Japan Diabetes Society
Japan Society for the Promotion of Science